Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-blind, Double-dummy, Active-controlled, Multi-centre Trial to Compare the Efficacy and Safety of CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) With Meropenem in Infections Caused by β-Lactamase (ESBL and MBL) Producing Gram-Negative Bacteria

NCT03477422 is registered in ClinicalTrials.gov with Venus Remedies Limited as lead sponsor.

NCT NCT03477422
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03477422 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-blind, Double-dummy, Active-controlled, Multi-centre Trial to Compare the Efficacy and Safety of CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) With Meropenem in Infections Caused by β-Lactamase (ESBL and MBL) Producing Gram-Negative Bacteria
Lead sponsor
Venus Remedies Limited
Phase
Phase 3
Overall status
Completed
Start date
January 11, 2014
Completion date
May 8, 2017
Enrollment
230 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

acute pyelonephritis, urinary tract infection complicated